Anticonvulsant hypersensitivity syndrome: Lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment

被引:33
作者
Bavdekar, SB [1 ]
Muranjan, MN [1 ]
Gogtay, NJ [1 ]
Kantharia, V [1 ]
Kshirsagar, NA [1 ]
机构
[1] Seth GS Med Coll & KEM Hosp, Dept Pediat, Bombay, Maharashtra, India
关键词
antiepileptic drugs; lymphocyte toxicity assay;
D O I
10.1345/aph.1E042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report a case of anticonvulsant hypersensitivity syndrome (AHS) precipitated by exposure to phenobarbital. CASE SUMMARY: An 11-year-old girl receiving phenobarbital developed fever, exfoliative skin rash, mucous membrane lesions, alopecia, and hepatic inflammation. Investigations ruled out an infectious etiology; an adverse event following phenobarbital administration was considered. Applying the Naranjo probability scale for objective causality assessment showed the adverse reaction was probably due to phenobarbital. The diagnosis was confirmed by in vitro lymphocyte toxicity assay, which demonstrated increased cell death following exposure to phenobarbital, as well as other aromatic anticonvulsants and lamotrigine. DISCUSSION: AHS is a rare, potentially fatal event with multisystem manifestations. It is reported following exposure to aromatic antiepileptics. The mechanism proposed for AHS is accumulation of toxic arene oxide metabolites due to a defect in epoxide hydrolase-mediated detoxification. Despite the difference in chemical structure of lamotrigine, in vitro susceptibility to AHS was demonstrated in our patient. CONCLUSIONS: Although AHS is a rare event, it should be suspected in patients who develop unexplained systemic manifestations following exposure to aromatic antiepileptics. The potential of lamotrigine to cause AHS should be remembered when this drug is used in subjects who have developed AHS on exposure to phenobarbital and other first-line antiepileptic agents.
引用
收藏
页码:1648 / 1650
页数:3
相关论文
共 9 条
  • [1] A seven-year-old boy with fever. Lymphadenopathy, hepatosplenomegaly, and prominent eosinophilia - Carbamazepine hypersensitivity reaction
    Gorlin, JB
    Connnolly, SA
    Scully, RE
    Ebb, DH
    Ferry, JA
    Gavarasana, SN
    Pasternack, MS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (08) : 577 - 584
  • [2] *J HOPK U, 2002, 132810 MIM J HOPK U
  • [3] LEEDER SJ, 1998, EPILIPSIA, V39, pS18
  • [4] Anticonvulsant hypersensitivity syndrome
    Morkunas, AR
    Miller, MB
    [J]. CRITICAL CARE CLINICS, 1997, 13 (04) : 727 - &
  • [5] A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS
    NARANJO, CA
    BUSTO, U
    SELLERS, EM
    SANDOR, P
    RUIZ, I
    ROBERTS, EA
    JANECEK, E
    DOMECQ, C
    GREENBLATT, DJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) : 239 - 245
  • [6] PIRMOHAMED M, 1991, BRIT J CLIN PHARMACO, V32, P741
  • [7] Lamotrigine-induced severe cutaneous adverse reactions
    Schlienger, RG
    Shapiro, LE
    Shear, NH
    [J]. EPILEPSIA, 1998, 39 : S22 - S26
  • [8] ANTICONVULSANT HYPERSENSITIVITY SYNDROME - INVITRO ASSESSMENT OF RISK
    SHEAR, NH
    SPIELBERG, SP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1988, 82 (06) : 1826 - 1832
  • [9] Anticonvulsant hypersensitivity syndrome in children - Incidence, prevention and management
    Verrotti, A
    Trotta, D
    Salladini, C
    Chiarelli, F
    [J]. CNS DRUGS, 2002, 16 (03) : 197 - 205